EUCTR2017-004417-42-FR进行中（未招募）1 期
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,955
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Participants that are currently enrolled in MSD-sponsored pembrolizumab trials and are receiving trial treatment or in a Follow-up Phase at the time KN587 is open. The parent trials must have completed all regulatory requirements and submissions, if any, or have fully addressed their primary endpoint(s) before all their participants roll over into KN587.
- •2. The participant (or legally acceptable representative if applicable) provides informed consent for the trial and agrees to follow study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •There are no exclusion criteria to participate in KN587.
研究者
相似试验
进行中（未招募）
1 期
Extension Study for Participants With Advanced Tumors in Pembrolizumab TrialsAdvanced TumorsMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2017-004417-42-EEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,955
进行中（未招募）
1 期
Extension Study for Participants With Advanced Tumors in Pembrolizumab TrialsAdvanced TumorsMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2017-004417-42-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.1,955
招募中
3 期
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.advanced tumor100386661002910710040900cancerNL-OMON52613Merck Sharp & Dohme (MSD)18
进行中（未招募）
1 期
Extension Study for Participants With Advanced Tumors in Pembrolizumab TrialsEUCTR2017-004417-42-IEMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1,955
进行中（未招募）
1 期
Extension Study for Participants With Advanced Tumors in Pembrolizumab TrialsAdvanced TumorsMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2017-004417-42-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,955